Introduction: Cutaneous Leishmaniasis (CL) is an endemic disease in developing countries. Glocantime has been recommended for CL treatment by W.H.O, there are some Restrictions in this case including high expense, side effects, frequent injections need, and incomplete efficacy. Cutaneous Leishmaniasis is an endemic disease in developing countries. Glocantime has been recommended for CL treatment by W.H.O, there are some Restrictions in this case including high expense, side effects, frequent injections need, and incomplete efficacy. The aim of the study was the efficacy of Synthesis and Leishmanicidal Evaluation of Aryl Immuno-5- Arylidine Thiazolidine 4- 1 derivative: An in vitro study. Materials and Methods: The design of the present probe was experimental (laboratory-trail); therefore, Iranian endemic species including Leishmania (L) tropica strain [MHOM/IR/NADIM3] was proliferated, and maintained in the standard culture. Then, the proper densities of Aryl Immuno-5- Arylidine Thiazolidine 4- 1 derivatives were provided and then sterilized and added to cultures containing parasite. Parasite numbers were counted in mentioned in cell proliferation ELISABrdu (Chemiluminescent). Results: Percentage of viability PMs Leishmania (L) tropica [MHOM/IR/NADIM3] in Concentrations of 1375, 2750, 5500 and 1100 mg/ml of 5-Arylidine-Immuno- Thiazolidine 4 one derivative and control showed statistically there was a significant difference, NOVA test, (P=0.000). And Percentage of viability PMs Leishmania (L) tropica [MHOM/IR/NADIM3] in Concentrations of 125, 250, 500 and 1000 mg/ml of Glocantime and control showed statistically there was a significant difference, ANOVA test, (P=0.000). Conclusion: According to the results, 5-Arylidine-Immuno- Thiazolidine 4 one derivative is effect and may make it possible to use them in the treatment of Cutaneous Leishmaniasis as a or alternative therapy; however, further studies are necessary and should be evaluated in cell culture and in vivo conditions to confirm it.